INS and metabolic dysfunction-associated steatohepatitis: Insulin treatment reduced mean blood glucose to normoglycemic levels in the NASH-STZ-HI group within the first week of treatment and remained stable and significantly lower compared to NASH-STZ for the remaining part of the study (p < 0.0001, Fig. 2).